Completed PHASE2 INTERVENTIONAL 4-arm NCT00310817

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

Sponsor: Novartis

Conditions Meningococcal Meningitis

Interventions MenACWY polysaccharide vaccine MenACWY-CRM conjugate vaccine, adjuvanted MenACWY-CRM conjugate vaccine, unadjuvanted

Updated 6 times since 2017 Last updated: Oct 6, 2015 Started: Mar 31, 2005 Primary completion: May 31, 2006 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00310817, this PHASE2 trial focuses on Meningococcal Meningitis and remains completed. Sponsored by Novartis, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Novartis Vaccines

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Samodzielny ZOZ, Lubartów, Poland
• Tampere, Finland